News - Interferon BETA-1B
WAYNE, N.J., Jan. 8, 2011 /PRNewswire/ --- Bayer HealthCare Pharmaceuticals has become aware of a broad United States market recall of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names.
SAN ANTONIO, June 3 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched a new tool using a technology that many people with multiple sclerosis (MS) already have in their pockets or purses - their iPhone.
WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of secondary progressive multiple sclerosis, Biogen Idec/Elan's Tysabri will remain Decision Resources' proprietary clinical gold standard through 2018.
EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
